Toru Ishikawa

60PUBLICATIONS
182CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)NeonatologyCardiology (incl. cardiovascular diseases)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (60)

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|Jun 22, 2026
Hepatic Steatosis Detected by Abdominal Ultrasonography Is Associated With Worse Prognosis in Underweight Patients.

|Jun 14, 2026
Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis.

|Jun 08, 2026
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Pageof 10

Frequent Collaborators

48 joint publications

Hidenori Toyoda

41 joint publications

Atsushi Hiraoka

40 joint publications

Toshifumi Tada

36 joint publications

Takeshi Hatanaka